HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Identification of a potential biomarker for FABP4 inhibition: the power of lipidomics in preclinical drug testing.

Abstract
The fatty acid binding protein 4 (FABP4) belongs to the family of lipid chaperones that control intracellular fluxes and compartmentalization of their respective ligands (e.g., fatty acids). FABP4, which is almost exclusively expressed in adipocytes and macrophages, contributes to the development of insulin resistance and atherosclerosis in mice. Lack of FABP4 protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice. Furthermore, total or macrophage-specific FABP4 deficiency is protective against atherosclerosis in apolipoprotein E-deficient mice. The FABP4 small-molecule inhibitor BMS309403 has demonstrated efficacy in mouse models for type 2 diabetes mellitus and atherosclerosis, resembling phenotypes of mice with FABP4 deficiency. However, despite the therapeutically attractive long-term effects of FABP4 inhibition, an acute biomarker for drug action is lacking. The authors applied mass spectrometry lipidomics analysis to in vitro and in vivo (plasma and adipose tissue) samples upon inhibitor treatment. They report the identification of a potential biomarker for acute in vivo FABP4 inhibition that is applicable for further investigations and can be implemented in simple and fast-flow injection mass spectrometry assays. In addition, this approach can be considered a proof-of-principle study that can be applied to other lipid-pathway targeting mechanisms.
AuthorsKarsten Suhre, Werner Römisch-Margl, Martin Hrabé de Angelis, Jerzy Adamski, Gerd Luippold, Robert Augustin
JournalJournal of biomolecular screening (J Biomol Screen) Vol. 16 Issue 5 Pg. 467-75 (Jun 2011) ISSN: 1552-454X [Electronic] United States
PMID21543640 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid
  • Biomarkers
  • Biphenyl Compounds
  • CCL2 protein, human
  • Chemokine CCL2
  • FABP4 protein, human
  • Fatty Acid-Binding Proteins
  • Pyrazoles
Topics
  • Adipocytes (drug effects, metabolism)
  • Adipose Tissue (metabolism)
  • Animals
  • Biomarkers (metabolism)
  • Biphenyl Compounds (pharmacology)
  • Cell Line, Tumor
  • Chemokine CCL2 (secretion)
  • Drug Evaluation, Preclinical
  • Fatty Acid-Binding Proteins (antagonists & inhibitors)
  • Humans
  • Lipid Metabolism (drug effects)
  • Macrophages (drug effects, metabolism)
  • Male
  • Mice
  • Pyrazoles (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: